Current status of clinical trials assessing oncolytic virus therapy for urological cancers

Oncolytic virus therapy: A new era of cancer treatment at dawn

(2016) Hiroshi Fukuhara et al.   CANCER SCIENCE

Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer

(2016) Robert Coffin   Immunotherapy

Treatment of Human Thyroid Carcinoma Cells with the G47delta Oncolytic Herpes Simplex Virus

(2015) Jia-Ni Wang et al.   Asian Pacific Journal of Cancer Prevention

2597 Phase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC)

(2015) S.G. Kim et al.   EUROPEAN JOURNAL OF CANCER

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G

(2015) Edgardo D. Carosella et al.   EUROPEAN UROLOGY

Emerging agents for the therapy of advanced prostate cancer

(2015) Amanda R Hathaway et al.   Future Oncology

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

(2015) Se Hoon Park et al.   MOLECULAR THERAPY

Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

(2015) Timothy P Cripe et al.   MOLECULAR THERAPY

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta

(2014) Jiani Wang et al.   Cancer Cell International

A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

(2014) James M Markert et al.   MOLECULAR THERAPY

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

(2013) T Wahlgren et al.   BRITISH JOURNAL OF CANCER

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer

(2013) James L. Gulley et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Suicide gene therapy in cancer: Where do we stand now?

(2012) Sónia Duarte et al.   CANCER LETTERS

Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress

(2012) Balveen Kaur et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?

(2012) Keith A. Lawson et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

(2012) James M. Burke et al.   JOURNAL OF UROLOGY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

(2011) Kelley A Parato et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma

(2011) Jia-Ni Wang et al.   Chinese Journal of Cancer

Virus therapy for bladder cancer

(2010) James Burke   CYTOKINE & GROWTH FACTOR REVIEWS

Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients

(2010) Richard Harrop et al.   JOURNAL OF IMMUNOTHERAPY

Treatment of metastatic renal cell carcinoma

(2010) Maxine Sun et al.   Nature Reviews Urology

Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures

(2009) B J Passer et al.   GENE THERAPY

Oncolytic virus therapy for prostate cancer

(2009) Hiroshi Fukuhara et al.   INTERNATIONAL JOURNAL OF UROLOGY

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

(2008) L. Vidal et al.   CLINICAL CANCER RESEARCH

Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle

(2008) Yoshifumi Kawaguchi et al.   INTERNATIONAL JOURNAL OF CANCER

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16

(2008) M Aghi et al.   ONCOGENE

Intravesical Treatments of Bladder Cancer: Review

(2008) Zancong Shen et al.   PHARMACEUTICAL RESEARCH